The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
β-Lactams Increase the Antibacterial Activity of Daptomycin against Clinical Methicillin-Resistant Staphylococcus aureus Strains and Prevent Selection of Daptomycin-Resistant Derivatives
Open accessAbstract
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged to be one of the most important pathogens both in health care and in community-onset infections. Daptomycin (DAP) is a cyclic anionic lipopeptide recommended for treatment of skin infections, bacteremia, and right-sided endocarditis caused by MRSA. Resistance to DAP (DAP r ) has been reported in MRSA and is mostly accompanied by a parallel decrease in oxacillin resistance, a process known as the “seesaw effect.” Our study provides evidence that the seesaw effect applies to other β-lactams and carbapenems of clinical use, including nafcillin (NAF), cefotaxime (CTX), amoxicillin-clavulanic (AMC), and imipenem (IMP), in heterogeneous DAP r MRSA strains but not in MRSA strains expressing homogeneous β-lactam resistance. The antibacterial efficacy of DAP in combination with β-lactams was evaluated in isogenic DAP-susceptible (DAP s )/Dap r MRSA strains originally obtained from patients that failed DAP monotherapy. Both in vitro (MIC, synergy-kill curve) and in vivo (wax worm model) approaches were used. In these models, DAP and a β-lactam proved to be highly synergistic against both heterogeneous and homogeneous clinical DAP r MRSA strains. Mechanistically, β-lactams induced a reduction in the cell net positive surface charge, reverting the increased repulsion provoked by DAP alone, an effect that may favor the binding of DAP to the cell surface. The ease of in vitro mutant selection was observed when DAP s MRSA strains were exposed to DAP. Importantly, the combination of DAP and a β-lactam prevented the selection of DAP r variants. In summary, our data show that the DAP–β-lactam combination may significantly enhance both the in vitro and in vivo efficacy of anti-MRSA therapeutic options against DAP r MRSA infections and represent an option in preventing DAP r selection in persistent or refractory MRSA infections.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Tenover, F. C., Arbeit, R. D., Goering, R. V., Mickelsen, P. A., Murray, B. E., Persing, D. H., & Swaminathan, B. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.9.2233-2239.1995 · Cited by 8,204
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir034 · Cited by 1,599
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Peschel, A., Otto, M., Jack, R. W., Kalbacher, H., Jung, G., & Götz, F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8405 · Cited by 994
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus
Bannerman, T. L., Hancock, G. A., Tenover, F. C., & Miller, J. M. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.3.551-555.1995 · Cited by 550
Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus
Friedman, L., Alder, J. D., & Silverman, J. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00039-06 · Cited by 454
Natural products to drugs: daptomycin and related lipopeptide antibiotics
Baltz, R. H., Miao, V., & Wrigley, S. K. (2005) · Natural Product Reports · doi:10.1039/b416648p · Cited by 393
Research works printed but not linked: 1
- NCCLS/CLSI. 2007. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A8, 8th ed. NCCLS/CLSI, Wayne, PA.
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Thabit, A. K., Crandon, J. L., & Nicolau, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.993381 · Cited by 160
Metadata
- Authors
- Mehta, S., Singh, C., Plata, K. B., Chanda, P. K., Paul, A., Riosa, S., Rosato, R. R., & Rosato, A. E.
- Affiliations
- Houston Methodist Research Institute (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-12
- Volume
- 56
- Issue
- 12
- Pages
- 6192-6200
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3497165
- OpenAlex
- W2146598854
- Cited by
- 142
- References
- 49
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 14 · 2017: 11 · 2016: 13 · 2015: 20 · 2014: 12 · 2013: 15 · 2012: 2
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI080688)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- daptomycin, methicillin-resistant Staphylococcus aureus, beta-lactam antibiotics, carbapenems, combination therapy, drug synergy, daptomycin resistance, seesaw effect, oxacillin resistance, nafcillin, cefotaxime, imipenem, mutant selection, cell surface charge, MRSA skin infection
- MeSH terms
- Animals, Anti-Bacterial Agents, Cefotaxime, DNA, Drug Synergism, Insecta, Larva, Microbial Sensitivity Tests, Mutation, Nafcillin, Oxacillin, Staphylococcal Infections, Imipenem, Daptomycin, Amoxicillin-Potassium Clavulanate Combination, Drug Resistance, Bacterial, beta-Lactams, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: β-Lactams Increase the Antibacterial Activity of Daptomycin against Clinical Methicillin-Resistant Staphylococcus aureus Strains and Prevent Selection of Daptomycin-Resistant Derivatives. https://app.cochat.ai/papers/10.1128/aac.01525-12
- The paper
- Mehta, S., Singh, C., Plata, K. B., Chanda, P. K., Paul, A., Riosa, S., Rosato, R. R., & Rosato, A. E. (2012). β-Lactams Increase the Antibacterial Activity of Daptomycin against Clinical Methicillin-Resistant Staphylococcus aureus Strains and Prevent Selection of Daptomycin-Resistant Derivatives. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01525-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.